AbbVie Stock Gains After Hiking FY21 Earnings Outlook, Annual Dividend

  • AbbVie Inc ABBV reports Q3 adjusted EPS of $3.33, higher than $2.83 reported a year ago and beating the consensus of $3.22.
  • Overall sales increased 11.2% Y/Y to $14.34 billion, almost in line with the consensus of $14.32 billion.
  • The immunology portfolio generated $6.67 billion in sales, +15.3% (14.9% on an operational basis).
  • Hematologic oncology portfolio sales were $1.87 billion, +8.4% (+8.1%).
  • Sales from the neuroscience portfolio reached $1.57 billion, +25.5% (+25%).
  • Aesthetics portfolio sales increased 29.3% (+27.7%) to $1.25 billion.
  • Adjusted gross margin expanded from 81.7% to 83.2%. The operating margin also improved from 48.8% to 51.1%.
  • FY21 guidance: AbbVie raises FY21 adjusted EPS guidance from $12.52 - $12.62 to $12.63 - $12.67 (consensus of $12.59).
  • The Company also increased the dividend by 8.5%, from $1.30 per share to $1.41, payable on February 15, 2022, to shareholders of record as of January 14, 2022.
  • Price Action: ABBV shares are up 3.03% at $113.00 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
▲▼
ticker
▲▼
name
▲▼
Actual EPS
▲▼
EPS Surprise
▲▼
Actual Rev
▲▼
Rev Surprise
▲▼
Posted In: BiotechEarningsLong IdeasNewsGuidanceDividendsHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!